More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Ozempic, originally prescribed for type 2 diabetes, is now widely used off-label for weight loss, but rapid results can lead ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Novo Nordisk’s UK unit has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to what was described as “serious breaches” of the ...